This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sequenom's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Sequenom, Inc. (SQNM)

Q2 2012 Earnings Conference Call

July 26, 2012 5:00 PM ET

Executives

Marcy Graham - Senior Director, Investor Relations

Harry Hixson - Chairman and CEO

Paul Maier – CFO

Ron Lindsay - Director and EVP

Bill Welch - SVP, Diagnostics

Dirk van den Boom - SVP, Research &Development



Analysts

Nandita Koshal - Barclays Capital

Bill Quirk - Piper Jaffray

Brian Weinstein - William Blair

Brandon Couillard – Jefferies & Co.

David Ferreiro – Oppenheimer & Co.

Zarak Khurshid - Wedbush Securities

Kevin DeGeeter - Ladenburg Thalmann & Co.

Junaid Husain – Dougherty & Company



Presentation

Operator

Good afternoon, and welcome to the Sequenom’s Second Quarter 2012 Earnings Conference Call. All participants will be in listen-only-mode. (Operator Instructions). After today’s presentation, there will be an opportunity to ask questions. (Operator Instructions). Please note this event is being recorded.

And I would now like to turn the conference over to Marcy Graham, Senior Director, Investor Relations. Please go ahead.

Marcy Graham

Thank you, Emmy. Welcome to the Sequenom conference call to discuss operating results for the second quarter of 2012. Joining me today are Dr. Harry Hixson, Chairman and CEO, Paul Maier, CFO, Ron Lindsay, Director and Executive Vice President of Research and Development, Bill Welch, Senior Vice President of Diagnostics and Dr. Dirk van den Boom, Senior Vice President of Research and Development, both of whom will join us later for the Q&A portion of our call.

This call is also being broadcast live over the web and will be available for replay through August, 4 th on the investor section of our website at www.sequenom.com. Before we begin, please note that this call will include a discussion of Sequenom and Sequenom CMM’s current plans and intentions regarding operations and commercialization, including diagnostic test projections, goals, diagnostics test enhancements, operational enhancements and other matters, as well as expectations regarding Sequenom’s future financial performance and reporting.

Statements that are not historical facts, but are forward-looking statements. Forward-looking statements are not guarantees of performance, they involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs